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Abstract
Development of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by
influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant
influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG
(HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains
of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated
mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to
cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and
2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly,
immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against
high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This
study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal
H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.
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Introduction
Influenza epidemics and pandemics caused by influenza A virus
(IAV) occur frequently. The first influenza pandemic of the 21st
century emerged in 2009, with a novel swine-origin influenza virus
(S-OIV) H1N1 as the causative agent. Originating in Mexico, it
rapidly spread to North America and then globally [1–4]. Of more
concern, however, is the continual outbreak of highly pathogenic
avian influenza (HPAI) H5N1, an influenza A subtype virus
circulating in poultry, which has caused hundreds of human diseases
with severe morbidity and high mortality since its re-emergence in
2003 (http://www.who.int/csr/disease/avian_influenza/country/
cases_table_2010_12_09/en/index.html). Although genetic analy-
sis of H5N1 isolated from humans revealed that all genes were of
avian origin, limited person-to-person transmission of H5N1 viruses
was identified [5]. Now the concern is that future influenza
epidemics may be caused by new virus strains derived from
mutations and/or reassortments of existing influenza viruses,
particularly HPAI H5N1. Therefore, the development of effective
preventive and therapeutic measures against IAV, particularly avian
H5N1, is urgently needed.
Vaccination is an important strategy to counteract influenza
pandemics. Current efforts to develop HPAI H5N1 vaccines are
mainly focused on inactivated vaccines, which have been
demonstrated to be effective in animal models for protection of
H5N1 infection and to induce neutralizing antibodies in about
70% of human volunteers [6–8]. The other H5N1 vaccine
candidates, such as those based on live-attenuated virus [9], viral
vectors [10], virus-like particles (VLP) [11], DNA vaccines [12]
and recombinant proteins [13], have also been tested in animal
models [14,15], and even evaluated in clinical trials [16].
However, because of the rapid mutation of hemagglutinin (HA)
protein of HPAI H5N1 virus, the cross-protective immunity of
these vaccines is fundamentally restricted, highly limiting their
potential use against divergent H5N1 viruses.
The above fact has implied that future H5N1 influenza vaccines
should be developed with more immunogenic, being able to
provide broader protection against various strains of H5N1 virus
infections. This may be achieved by upgrading vaccine formulas
with effective adjuvants for either inactivated or live-attenuated
IAV vaccines [15], designing novel vaccine components that rely
on conserved sequences or universal epitopes of viral proteins,
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such as matrix protein 2 (M2), HA, and nucleoprotein (NP)
[14,17], updating vaccine delivery systems [18], or combining viral
proteins with other components [19]. The above findings
represent a significant advancement towards the development of
more efficacious H5N1 influenza vaccines.
Fc of IgG is considered an important fusion tag for co-
expression with several viral proteins, such as receptor-binding
domain (RBD) of severe acute respiratory syndrome coronavirus
(SARS-CoV), in order to facilitate purification and subsequent
immunogenicity of the proteins [20,21]. For example, fusion of Fc
to HIV-1 protein has also been shown to increase the
immunogenicity of fusion proteins and to elicit neutralizing
antibody responses [22,23]. This is explained by the ability of Fc
to promote correct folding of the fusion proteins following
expression and the possibility that IgG Fc may help to enhance
binding to antigen-presenting cells (APCs) and cell lines expressing
Fc receptors (FcR) [22,24]. The foldon (Fd) sequence derived from
native T4 phage fibritin has been typically incorporated at the
C-terminus of collagen-like protein molecules to facilitate
stabilization of protein trimer or oligomer [25,26], indicating that
C-terminal Fd is essential for correct trimerization and folding of
the protein [27].
In this study, we designed two recombinant influenza vaccines
based on the recombinant proteins encoding HA1 of a H5N1 virus
fused to either Fc of pFUSE-hIgG1-Fc2 (human IgG Fc, thereafter
named Fc) or Fd plus Fc. We then tested their immune responses
and cross-protection against divergent strains of H5N1 virus in a
mouse model. The developed vaccine candidates were shown to
induce highly potent neutralizing antibodies that protected
vaccinated mice against lethal challenge of all tested strains of
H5N1 virus infection.
Results
Detection of Expression of HA1-Fc and HA1-Fdc Proteins
The HA1 of A/Anhui/1/2005(H5N1) (AH/1) containing 320
amino acids (residues +3-322) were fused in-frame to Fc or Fd plus
Fc to form recombinant HA1-Fc and HA1-Fdc, respectively, with
IL2ss of the Fc vector as the signal sequence. The recombinant
proteins of HA1-Fc and HA1-Fdc will be expressed in the culture
supernatant of transfected 293T cells (Fig. 1) [28], followed by
purification of the proteins from the supernatant. Both proteins
maintained a high level of expression, with approximately 10 mg
obtained in 250 ml culture medium. After purification, the
proteins were analyzed by SDS-PAGE, followed by Coomassie
blue staining, and reactivity was determined using a HA-specific
monoclonal antibody (mAb) developed in our laboratory [29]. As
shown in Fig. 2A, one clear band was observed in samples of HA1-
Fc and HA1-Fdc proteins analyzed by SDS-PAGE, indicating that
highly purified proteins could be obtained from transfected culture
supernatant. The purified recombinant proteins of HA1 could be
recognized by the HA-specific mAb, as indicated by Western blot
(Fig. 2B), revealing their high specificity to the HA of H5N1.
HA1-Fc and HA1-Fdc Proteins Induced Strong Antibody
Responses to the Homogenous HA1 Proteins and an
Inactivated Heterologous H5N1 Virus
The antibody responses in the sera of mice vaccinated with
HA1-Fc and HA1-Fdc proteins were evaluated by ELISA. As
shown in Fig. 3A, both proteins induced IgG antibody responses
specific to the purified HA1-Fc and HA1-Fdc proteins, with the
antibody titer quickly reaching at high level after the first
vaccination, then slightly increasing after each boost. An average
end-point antibody titer of 1:2.16108 was detected in mouse sera
collected at 10 days post-last boost (Fig. 3B). Antibody levels were
further detected by coating the ELISA plates with a HA1 protein
without fusing Fc and Fd to eliminate antibody response
potentially induced by the fusion tag Fc and/or Fd. As illustrated
in Fig. 3C, sera of mice vaccinated with the fusion proteins,
particularly HA1-Fdc, reacted strongly with this HA1 protein,
reaching an end-point titer of 1:1.36107, demonstrating that the
antibody responses induced by the expressed proteins were mainly
targeted the HA1 protein. It was further shown that the induced
Figure 1. Structure of HA protein of AH/1 and construction of
recombinant HA1-Fc and HA1-Fdc proteins. (A) Structure of HA
protein of H5N1 AH/1 strain. The HA protein of AH/1 H5N1 virus
consists of signal peptide (SP, residues 1–18), HA1 (residues 19–345,
corresponding to +3-329aa) and HA2 (residues 346–567, corresponding
to +330-551aa) fragments spanned by a protease cleavage site RERRRKR
between HA1 and HA2. Amino acid 19 of HA1 of AH/1 corresponds to
H5N1(A/Vietnam/1203/2004) amino acid +3 [28]. Schematic structures
of recombinant HA1-Fc (B) and HA1-Fdc proteins (C). The original SP of
HA of H5N1 virus was replaced by IL2ss signal sequence in the Fc
vector, constituting HA1-Fc. HA1-Fdc was constructed by fusing Fd
sequence to the C-terminus of HA1, followed by insertion into the Fc
vector.
doi:10.1371/journal.pone.0016555.g001
Figure 2. Analysis of the expression of HA1-Fc and HA1-Fdc
proteins. The expression of HA1-Fc and HA1-Fdc proteins were
performed by SDS-PAGE and Coomassie blue staining (A), and Western
blot (B) using a HA-specific mAb. The protein molecular weight marker
(kDa) is indicated on the left.
doi:10.1371/journal.pone.0016555.g002
HA1 Vaccine Induced Cross-Protection against H5N1
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16555
IgG antibodies could also react with an inactivated heterologous
virus A/VietNam/1194/2004(H5N1) (VN/1194), having a sim-
ilar end-point antibody titer of 1:1.36107 (Fig. 3D). No IgG
antibody response was detectable in the sera of control mice
injected with PBS (Fig. 3).
IgG1 and IgG2a subtypes induced by HA1-Fc and HA1-Fdc
proteins were detected in the mouse sera collected at 10 days post-
last vaccination. The results showed that both HA1-Fc and HA1-
Fdc elicited similar levels of IgG1 (Th2-associated, Fig. 4A) and
IgG2a (Th1-associated, Fig. 4B) antibody responses specific to the
HA1 proteins, reaching an end-point antibody titer of 1:2.16108.
No IgG1 or IgG2a antibody response was found in the sera of PBS
control mice (Fig. 4).
The above data suggest that expressed HA1-Fc and HA1-Fdc
proteins are able to elicit high titers of antibody responses specific
to the HA1 proteins of homogeneous and heterogeneous H5N1
viruses, implying their high immunogenicity in stimulating strong
humoral immune responses in the vaccinated mice.
HA1-Fc and HA1-Fdc Proteins Elicited High Titers of
Neutralizing Antibodies against Infection by Different
Clades of H5N1 Strains
Levels of neutralizing antibodies in the vaccinated mice were
evaluated in cell cultures infected with four clades (clade 0, 1, 2.2,
2.3) of H5N1 pseudoviruses [29] and three clades (clade 0, 1, 2.3.4)
of H5N1 live viruses (Table 1). Fig. 5A showed that HA1-Fc and
HA1-Fdc were able to induce highly potent neutralizing antibody
responses in the vaccinated mice, which neutralized not only
homologous AH-HA strain but also heterologous strains of H5N1
pseudoviruses, including HK-HA, 1194-HA, QH-HA, and XJ-HA.
The results also demonstrated that induced antibodies could
neutralize infections of heterologous strains of H5N1 live viruses,
such as HK/156, VN/1194, and SZ/406H, reaching the highest
titer of 1:8.5610263.76102 against SZ/406HH5N1 virus (Fig. 5B).
In addition, these antibodies could inhibit hemagglutination of the
above three H5N1 live viruses, with the average hemagglutination
inhibition (HI) titer $1:1.06103 (Fig. 5C). Notably, neutralizing
Figure 3. Detection of total IgG antibody responses by ELISA in HA1-Fc- and HA1-Fdc-vaccinated mouse sera. PBS was used as the
negative control. (A) Reactivity of IgG antibody with HA1-Fc and HA1-Fdc proteins. The HA1-specific IgG was detected using sera (1:3,000) from mice
before (pre-immune) and 10 days after each vaccination. The data are presented as mean A450 6 standard deviation (SD) of five mice per group.
Ability of IgG binding to HA1-Fc and HA1-Fdc proteins (B), HA1 protein without Fd and Fc (C), and VN/1194 inactivated H5N1 virus (D), respectively,
was detected using mouse sera from 10 days post-last vaccination. The data are presented as mean A4506SD of five mice per group at various
dilution points.
doi:10.1371/journal.pone.0016555.g003
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antibodies induced by HA1-Fdc protein were greater than those
induced by HA1-Fc protein, showing a significantly higher level of
inhibition to infections of 1194-HA, QH-HA, XJ-HA and AH-HA
H5N1 pseudoviruses (P,0.05). In contrast, PBS control group only
elicited a background level of neutralizing and HI antibody titers in
the tested H5N1 pseudoviruses and live viruses (Fig. 5).
HA1-Fdc Completely Protected Mice against High-Dose
Lethal Challenge of Three Clades of H5N1 Strains
To examine the cross-protective effect induced by HA1-Fc and
HA1-Fdc proteins, vaccinated mice were challenged with 10 50%
lethal dose (10 LD50) of the above three H5N1 live viruses 10–12
days post-last vaccination. All vaccinated mice survived challenge
with HK/156 (Fig. 6A) and SZ/406H (Fig. 6C), suggesting that
the recombinant protein-based vaccines may completely protect
mice against challenges with clade 0 and 2.3.4 strains of H5N1
virus. All mice vaccinated with HA1-Fdc also survived challenge
with VN/1194, whereas about 10% of HA1-Fc-vaccinated mice
did not survive from the challenge with this virus (Fig. 6B). In
contrast, no control mice injected with PBS survived the challenge
with any of HK/156, VN/1194 and SZ/406H H5N1 viruses
(Fig. 6). These results demonstrated that vaccination with two
fusion proteins, particularly HA1-Fdc, could provide cross-clade
protection against divergent strains of H5N1 virus infection.
Vaccination of HA1-Fc and HA1-Fdc Proteins Reduced
Virus Replication and Limited Lung Damage in the Mice
Infected by Divergent Strains of H5N1 Virus
The cross-protective effect elicited by HA1-Fc and HA1-Fdc
proteins was further evaluated by detection of the viral load and
histopathological changes in lung tissues of mice collected at day 5
post-virus challenge. Fig. 7 revealed that viral RNA was
undetectable in the HA1-Fc- and HA1-Fdc-vaccinated mice
challenged with VN/1194 virus, but a high level of viral RNA
(8.6610867.46108 copies/lung tissues) was detected in the
control mice injected with PBS. Lung tissues of mice vaccinated
with HA1-Fc and HA1-Fdc also exhibited significantly lower level
of viral RNA than those of PBS control group after challenge with
HK/156 and SZ/406H virus, respectively (P,0.05). These results
suggest that the immunity induced by the recombinant fusion
proteins is able to highly suppress virus replication in the
vaccinated mouse lungs.
Examination of the H&E-stained lung tissues from virus-
challenged mice demonstrated that all of the control mice injected
with PBS developed a high degree of histopathological damage,
including serious interstitial pneumonia and significant inflamma-
tion, which were characterized by diffused alveoli collapse,
predominant lymphocyte infiltration, epithelial cell degeneration,
pulmonary vascular dilatation and congestion, and focal hemor-
rhage and exudation. In contrast, mice receiving HA1-Fc and
HA1-Fdc vaccines only presented slightly broadened interstitial
spaces with little lymphocyte infiltration after challenge with all
H5N1 viruses covering three different clades (Fig. 8).
Figure 4. Measurement of IgG1 and IgG2a antibody titers by
ELISA in HA1-Fc- and HA1-Fdc-vaccianted mouse sera. PBS was
used as the negative control. Ability of IgG1 (A) and IgG2a (B)
antibodies binds to the HA1 protein was detected using sera from 10
days post-last vaccination. The data are presented as mean A4506SD of
five mice per group at various dilution points.
doi:10.1371/journal.pone.0016555.g004
Table 1. Summary of H5N1 pseudovirus and live virus strains used in the study.
Virus name Virus strain Virus type Source Clade
Pathogenicity
in humans
HK-HA A/Hong Kong/156/97 Pseudovirus Heterologous 0 No
1194-HA A/VietNam/1194/2004 Pseudovirus Heterologous 1 No
QH-HA A/Qinghai/59/05 Pseudovirus Heterologous 2.2 No
XJ-HA A/Xinjiang/1/2006 Pseudovirus Heterologous 2.2 No
AH-HA A/Anhui/1/2005 Pseudovirus Homologous 2.3 No
HK/156 A/Hong Kong/156/97 Live virus Heterologous 0 High
VN/1194 A/VietNam/1194/2004 Live virus Heterologous 1 High
SZ/406H A/Shenzhen/406H/06 Live virus Heterologous 2.3.4 High
doi:10.1371/journal.pone.0016555.t001
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Figure 5. Assessment of neutralizing antibody and HI antibody titers in HA1-Fc- and HA1-Fdc-vaccinated mouse sera. Sera were
collected at 10 days post-last vaccination. PBS was used as the negative control. (A) Neutralizing antibody titers against HA of heterologous (HK-HA,
1194-HA, QH-HA and XJ-HA) and homologous (AH-HA) strains of H5N1 pseudovirus. The data are presented as mean 50% neutralizing antibody titer
(NT50) 6SD from five mice per group. * indicates significant difference (P,0.05) between HA1-Fc and HA1-Fdc vaccination groups. (B) Neutralizing
HA1 Vaccine Induced Cross-Protection against H5N1
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Discussion
Antibody responses provide essential immunity against infection
of IAVs [30]. As the main surface protein of the virus, HA of
H5N1 virus serves as an important target for induction of specific
antibodies with neutralizing activity and/or protective immunity
against HAPI H5N1 virus [31,32], and it has a greater
contribution than other viral proteins, such as NA, NP and M2,
to the induction of neutralizing antibodies and/or protection
[31,33]. HA-based vaccines have been shown to elicit higher titers
of neutralizing antibodies to prevent influenza virus infection in
tested animals [14,18,34]. In addition, human clinical trials of the
HA-containing H5N1 vaccines have revealed the production of
strong and broad antibody responses after vaccine injection
[35,36]. However, current influenza vaccines have failed to
provide sufficient protection against infections of rapidly mutated
influenza viruses. Thus, novel strategies are urgently needed to
develop vaccines potentially inducing cross-clade protection
against multiple strains of influenza viruses.
Fc fragment of human IgG has been previously used as a fusion
compartment to improve immunogenicity of the proposed
proteins [20,21,23]. The underlying mechanism of Fc fusion
protein-based vaccines may be partially due to that proteins with
Fc could bind to cells with FcR, while the latter plays important
roles in the clearance of virus infections and protection against
virus challenge via FcR-mediated phagocytosis [37].
Indeed, our study has demonstrated that both Fc-containing
influenza vaccine candidates, HA1-Fc and HA1-Fdc, were able to
elicit strong HA1-specific antibody responses and to neutralize
divergent strains of homologous and heterogeneous H5N1
pseudoviruses, as well as heterologous live virus. Importantly,
both HA1-Fc and HA1-Fdc proteins could elicit potent protective
immunity in the immunized mice against challenges of at least
three heterogeneous strains of H5N1 viruses.
In addition to Fc, another component, Fd, could also be
considered as a fusion partner to help increasing immunogenicity
of recombinant vaccines. This is because that Fd, a trimeric motif,
antibody titers against heterologous strains (HK/156, VN/1194 and SZ/406H) of H5N1 live virus. The titers of neutralizing antibodies were determined
as in Materials and Methods, and are presented as mean NT506SD of five mice per group. (C) HI antibody titers against heterologous strains (HK/156,
VN/1194 and SZ/406H) of H5N1 live virus. The HI titers were determined as the highest serum dilution indicating hemagglutinating activity, and are
expressed as mean 6 SD of five mice per group.
doi:10.1371/journal.pone.0016555.g005
Figure 6. Cross-clade protection of HA1-Fc- or HA1-Fdc-
vaccinated mice against lethal H5N1 virus challenge. HA1-Fc-
and HA1-Fdc-vaccinated mice were challenged with 10 LD50 of three
clades (clade 0: HK/156, clade 1: VN/1194, and clade 2.3.4: SZ/406H) of
H5N1 virus. PBS was used as the negative control. Groups of 10 mice
were observed for survival for 21 days post-virus challenge, and
corresponding survival rates were calculated. Survival rate (%) of mice
challenged with HK/156 (A), VN/1194 (B), and SZ/406H (C) H5N1 virus
was shown.
doi:10.1371/journal.pone.0016555.g006
Figure 7. Detection of viral RNA copies by quantitative reverse-
transcription PCR (Q-RT-PCR) in lung tissues of H5N1 virus-
challenged mice. Titers of HK/156, VN/1194 and SZ/406H H5N1 virus
were determined in lung tissues of the mice vaccinated with HA1-Fc
and HA1-Fdc proteins, respectively. Mice vaccinated with PBS were
used as the negative control. The data are expressed as mean 6 SD of
RNA copies per lung tissues from five mice per group.
doi:10.1371/journal.pone.0016555.g007
HA1 Vaccine Induced Cross-Protection against H5N1
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can maintain the native trimeric conformation of viral envelope
proteins, thus enhancing vaccine efficacy [25,32]. For example, a
recombinant protein expressing HIV-1 gp41 NHR fused with Fd
exhibited trimeric conformation and possessed potent anti-HIV-1
activity against a broad spectrum of HIV-1 strains [38].
In this study, we found that HA1-Fdc induced higher
neutralizing antibodies than HA1-Fc against several strains of
pseudoviruses and VN/1194 H5N1 live virus (Fig. 5), and stronger
protective immunity than HA1-Fc against challenge with H5N1
strain VN/1194 (Fig. 6B). These results confirm that Fd plays a
role in maintaining the native conformation of neutralizing
epitopes in the oligomeric immunogen to induce stronger immune
response in the vaccinated animals [38].
In summary, we have designed and constructed two recombi-
nant influenza vaccine candidates by fusion of viral HA1 fragment,
a major target of H5N1 influenza vaccines, with Fc of human IgG
and/or Fd. In this proof-of-concept study, we first demonstrated
that the fusion of viral HA1 antigen, with either Fc alone or both
Fd and Fc, was able to induce cross-neutralizing antibodies strong
enough against various subtypes of H5N1 virus, which, in turn,
could provide cross-protection against infections of different clades
of H5N1 virus in cell cultures in vitro and in mouse models in vivo.
Thus, our data suggest the possibility of developing universal
H5N1 influenza vaccines by using such innovative strategies as
fusion of viral antigens with Fd and Fc, as reported in this study.
Future studies will be needed to elucidate the mechanism of the
cross-protective immunity induced by the proposed candidate
vaccines.
Materials and Methods
Ethics Statement
The study of animals was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and
University of Hong Kong. All experimental protocols followed the
standard operating procedures of the approved biosafety level-3
(BSL-3) animal facilities and were approved by the Committee on
the Use of Live Animals in Teaching and Research of the
University of Hong Kong (CULATR Ref No.: 746-03) [39].
Construction, Expression, and Purification of
Recombinant HA1-Fc and HA1-Fdc Proteins
The genes encoding HA1 of H5N1 were amplified by PCR
using codon-optimized full-length HA of AH/1 (accession No.
ABD28180) as the template and inserted into the Fc expression
vector (InvivoGen, San Diego, CA) encoding the HA1-Fc vaccine.
The Fd sequence derived from bacteriophage T4 fibritin was fused
to the C-terminus of HA1 sequences by PCR with overlapping
primers, followed by insertion into the Fc expression vector to
encode the HA1-Fdc vaccine (Fig. 1). The recombinant HA1-Fc
and HA1-Fdc proteins were expressed as previously described [40]
with some modifications. Briefly, the sequence-confirmed recom-
binant plasmids were transfected into 293T cells (ATCC,
Manassas, VA) seeded 24 h prior to transfection, using the
calcium phosphate method. Culture medium was replaced by
fresh OPTI-MEM I Medium (Invitrogen, Carlsbad, CA) 10 h
later, and supernatant was collected 72 h post-transfection. The
recombinant HA1-Fc and HA1-Fdc proteins in the supernatant
were purified by Protein A affinity chromatography (GE
Healthcare, Piscataway, NJ) according to the manufacturer’s
instructions.
Western Blot
The purified HA1-Fc and HA1-Fdc proteins were analyzed by
SDS-PAGE and Western blot as previously described [41] using
an anti-HA mAb developed in our laboratories [29]. Briefly,
purified proteins (10 mg) were separated by 10–20% Tricine gels
(Invitrogen) and transferred to nitrocellulose membranes. After
blocking overnight at 4uC, the blots were incubated with HA-
specific mAb (1:1,000) for 1 h at room temperature. After three
washes, the blots were then incubated with horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG (1:5,000, Invitrogen) for
1 h at room temperature. Signals were visualized with ECL
Western blot substrate reagents and Amersham Hyperfilm (GE
Healthcare).
Mouse Vaccination and Virus Challenge
Female BALB/c mice at 6–8 weeks were kept in BSL-3 housing
and given access to standard pellet feed and water ad libitum.
Mice (45 mice/group) were subcutaneously (s.c.) primed-vaccinat-
ed with 20 mg/mouse of purified HA1-Fc and HA1-Fdc proteins
re-suspended in PBS in the presence of Sigma Adjuvant System
(SAS, Sigma, St. Louis, MO) and boosted twice with 10 mg/mouse
of immunogen containing SAS at 3-week intervals. Control mice
were s.c. injected with the same volume of PBS-SAS. Sera were
collected before immunization and 10 days post-each vaccination
to detect HA and neutralizing antibodies. Mice were intranasally
(i.n.) challenged with 10 LD50 of three clades of H5N1 virus, i.e.,
clade 0: HK/156, clade 1: VN/1194, and clade 2.3.4: SZ/406H,
respectively (15 mice/group), at 10–12 days after the last
vaccination. Infected mice were observed daily for 21 days or
until death. Five mice/group were sacrificed on day 5 post-
Figure 8. Evaluation of histopathological changes in lung
tissues of H5N1 virus-challenged mice. HA1-Fc- and HA1-Fdc-
vaccinated mice were challenged with 10 LD50 of three clades (clade 0:
HK/156, clade 1: VN/1194, and clade 2.3.4: SZ/406H) of H5N1, and lung
tissues were collected at day 5 post-challenge. Lung tissues from mice
injected with PBS and those of uninfected mice were used as negative
and normal controls, respectively. All sections of lung tissues were
stained with hematoxylin and eosin (H&E) and observed under light
microscope (magnification, 1006). Representative image of histopath-
ological damage from mice challenged with HK/156 (A), VN/1194 (B),
and SZ/406H (C) H5N1 virus was shown.
doi:10.1371/journal.pone.0016555.g008
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challenge, and lung samples were collected for virological and
histopathological detection.
ELISA
The antibody response was evaluated by ELISA in collected
mouse sera as previously described [42]. Briefly, 96-well ELISA
plates were pre-coated respectively with recombinant HA1-Fc and
HA1-Fdc fusion proteins, HA1 protein without Fd and Fc, and
inactivated H5N1 virus (VN/1194) overnight at 4uC and blocked
with 2% non-fat milk at 37uC for 2 h. Serially diluted mouse sera
were added to the plates and incubated at 37uC for 1 h, followed
by four washes. Bound antibodies were incubated with HRP-
conjugated goat anti-mouse IgG, IgG1 (Invitrogen), and IgG2a
(Bethyl Laboratories, Montgomery, TX) for 1 h at 37uC. The
reaction was visualized by substrate 3,39,5,59-tetramethylbenzidine
(TMB) (Invitrogen) and stopped by 1N H2SO4. The absorbance at
450 nm (A450) was measured by ELISA plate reader (Tecan, San
Jose, CA).
Pseudovirus Neutralization Assay
The titer of neutralizing antibodies was detected in mouse sera by
H5N1 pseudovirus neutralization assay as previously described
[29]. Briefly, 293T cells were co-transfected with a plasmid
encoding Env-defective, luciferase-expressing HIV-1 genome
(pNL4-3.luc.RE) and each of the plasmids encoding HA of
homologous AH-HA and heterologous HK-HA, 1194-HA, QH-
HA and XJ-HA, respectively, using the calcium phosphate method.
Exogenous bacterial neuraminidase (NA) (Sigma) was added 24 and
48 h later, and supernatants were harvested 72 h post-transfection
for single-cycle infection. The pseudovirus-containing supernatants
were incubated with serially diluted mouse sera at 37uC for 1 h
before adding to 293T cells. Fresh medium was added 24 h later,
followed by lysing cells 72 h later using cell lysis buffer (Promega,
Madison, WI) and transferring the lysates into 96-well luminometer
plates. Luciferase substrate (Promega) was added to the plates, and
relative luciferase activity was determined in an Ultra 384
luminometer (Tecan). The neutralization of HA pseudovirus was
calculated [43] and presented as NT50.
H5N1 Virus Neutralization Assay
Titers of neutralizing antibodies of vaccinated mice were
detected by neutralization assay as described previously [39,44].
Briefly, serial two-fold diluted mouse sera were respectively mixed
with 20 plaque forming units (PFU) of HK/156, VN/1194 and
SZ/406H (H5N1) and incubated at 37uC for 1 h before adding to
MDCK cells. Medium was replaced with fresh DMEM 1 h later,
and cell culture was continued for 72 h at 37uC. Viral cytopathic
effect (CPE) was observed daily and recorded on day 3 post-
infection. The neutralizing antibody titer was determined based on
the highest dilution of each serum, which completely suppressed
CPE induced by the virus in .50% of the wells.
HI Assay
HI assay was carried out as previously described [44–46] with
some modifications. Briefly, serial dilutions of mouse sera were
incubated with equal volumes of HK/156, VN/1194 and SZ/
406H H5N1 virus, respectively, for 1 h at room temperature,
followed by addition of equal volumes of 0.5% chicken red blood
cells for 30 min at room temperature. The HI antibody titers were
expressed as the highest serum dilution that completely inhibited
hemagglutinating activity.
Virological Tests
The viral RNA copies in lung tissues were quantified by Q-RT-
PCR as previously described [39]. Briefly, total RNA in lysed lung
tissues was extracted by using RNeasy Mini kit (Qiagen, Valencia,
CA) and reverse-transcribed to cDNA by using applied Super-
Script II Reverse Transcriptase (Invitrogen). Viral cDNA was
synthesized by Superscript RT II (Invitrogen) using Uni12 primer
(AGCAAAAGC). Real-time PCR was performed on the Light-
Cycler 480 system (Roche Applied Sciences) using SYBR Green I
Master (Roche) with gene-specific primer pairs (for HK/156,
forward primer: 59-TGTCAAGAAAGGAGACTCAGC-39, re-
verse primer: 59-ACCATCTACCATTCCCTGC-39; for VN/
1194, forward primer: 59-ATACACCCTCTCACCATCGG-39,
reverse primer: 59-ACCATCTACCATTCCCTGCC-39; for SZ/
406H, forward primer: 59-ATACACCCTCTCACCATCGG-39,
reverse primer: 59-ACCATCTACCATTCCCTGC-39) targeting
the H1 gene of different strains of H5N1 virus. The pcDNA3.1
plasmid, which contains the cloned H1 gene of the virus, was
applied as the standard.
Histopathological Analysis
The lung tissues of challenged mice were immediately fixed in
10% formalin and embedded in paraffin wax. Sections 4–6 mm in
thickness were made and mounted on slides. Histopathological
changes caused by H5N1 virus infection were examined by H&E
staining and viewed under light microscope as previously
described [39,47].
Statistical Analysis
Values were presented as mean with SD. Statistical significance
among different vaccination groups was calculated by Student’s t
test using Stata statistical software. P values less than 0.05 were
considered significant.
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